| Name | Title | Contact Details |
|---|
Evolve BioSystems is a spin-out from the Foods For Health Institute (FFHI) at the University of California, Davis. The company builds on more than a decade of research into the infant gut microbiome and its unique interaction with breast milk components, established by the founding scientists including Bruce German, David Mills, Carlito Lebrilla, Daniela Barile and Samara Freeman. Their fundamental research and translational clinical trials have been enabled by more than $15 million in federal and private grants since 2004. Under the leadership of CEO Dr. David Kyle, Evolve completed a $1 million seed funding round in mid-2014, a $9 million Series A round in August 2015 and most recently a $20 million Series B capital raise in 2017. Evolve has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering, with a series of upcoming trials scheduled across both human and animal health applications. With a strong portfolio of intellectual property developed at UC Davis, a world-class management team plus blue-chip investors, and an unwavering dedication to allowing science to direct our product development, Evolve continues to expand it`s pipeline of next generation microbiome-based solutions to establish, restore, and maintain a healthy gut microbiome.
Empowering the industry with the resources, expertise, and capital to help accelerate the advancement and adoption of cell and gene therapies.
ALERT Life Sciences Computing is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases. Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019.
RuiYi is focused on the discovery and development of novel biologic therapeutics that have the potential to be disruptive globally. In addition to RYI-018 and RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company's technologies, including the iCAPS (intramembranous Conformation Antigen Presenting System). Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. RuiYi's executive management team has offices in La Jolla, California, and RuiYi's discovery efforts and research facility are located in in the Zhangjiang Hi-Tech Park in Pudong, Shanghai, China.